| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Garrison J B Dyck, Zaid H Maayah, Dean T Eurich, Jason R B Dyc. Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review. Schizophrenia bulletin open. vol 3. issue 1. 2024-08-15. PMID:39144756. |
however, studies have shown that another major cannabinoid found in cannabis, cannabidiol (cbd), may be a potential alternative or adjunctive treatment for psychosis and schizophrenia. |
2024-08-15 |
2024-08-17 |
Not clear |
| Zhikun Li, Diptendu Mukherjee, Bea Duric, Isabelle Austin-Zimmerman, Giulia Trotta, Edoardo Spinazzola, Diego Quattrone, Robin M Murray, Marta Di Fort. Systematic review and meta-analysis on the effects of chronic peri-adolescent cannabinoid exposure on schizophrenia-like behaviour in rodents. Molecular psychiatry. 2024-08-01. PMID:39090371. |
the link between cannabis use and schizophrenia is well-established in epidemiological studies, especially among adolescents with early-onset use. |
2024-08-01 |
2024-08-05 |
Not clear |
| Jes Sebastian Denis Völker, M D Ph D Ioana Valentina Micluția, Ramona-Cristina Vinaș. Investigating Cannabidiol's Potential as a Supplementary Treatment for Schizophrenia: A Narrative Review. European journal of pharmacology. 2024-07-28. PMID:39068976. |
cannabidiol (cbd), a nonpsychoactive compound in cannabis sativa, has been extensively explored for its therapeutic potential in treating psychiatric disorders, including schizophrenia. |
2024-07-28 |
2024-08-02 |
Not clear |
| Delali Fiagbe, Ama Kyerewaa Edwin, Eugene K Dordoye, Dzifa Dellor, Adwoa Gyamera, Emmanuel Dziworn. The Ethical Dilemma of Balancing Confidentiality and Duty to Protect: A Case Report of Comorbid Schizophrenia and Cannabis Use Disorder with Homicidal Thoughts. Nigerian medical journal : journal of the Nigeria Medical Association. vol 64. issue 3. 2024-07-08. PMID:38974070. |
the ethical dilemma of balancing confidentiality and duty to protect: a case report of comorbid schizophrenia and cannabis use disorder with homicidal thoughts. |
2024-07-08 |
2024-07-11 |
Not clear |
| Delali Fiagbe, Ama Kyerewaa Edwin, Eugene K Dordoye, Dzifa Dellor, Adwoa Gyamera, Emmanuel Dziworn. The Ethical Dilemma of Balancing Confidentiality and Duty to Protect: A Case Report of Comorbid Schizophrenia and Cannabis Use Disorder with Homicidal Thoughts. Nigerian medical journal : journal of the Nigeria Medical Association. vol 64. issue 3. 2024-07-08. PMID:38974070. |
this is a report of a 29-year-old female with a history of schizophrenia and cannabis use disorder who presented with auditory hallucinations that asked her to kill her immediate supervisor. |
2024-07-08 |
2024-07-11 |
Not clear |
| Emma C Johnson, Isabelle Austin-Zimmerman, Hayley H A Thorpe, Daniel F Levey, David A A Baranger, Sarah M C Colbert, Ditte Demontis, Jibran Y Khokhar, Lea K Davis, Howard J Edenberg, Marta Di Forti, Sandra Sanchez-Roige, Joel Gelernter, Arpana Agrawa. Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024-06-21. PMID:38906991. |
individuals with schizophrenia frequently experience co-occurring substance use, including tobacco smoking and heavy cannabis use, and substance use disorders. |
2024-06-21 |
2024-06-24 |
Not clear |
| Emma C Johnson, Isabelle Austin-Zimmerman, Hayley H A Thorpe, Daniel F Levey, David A A Baranger, Sarah M C Colbert, Ditte Demontis, Jibran Y Khokhar, Lea K Davis, Howard J Edenberg, Marta Di Forti, Sandra Sanchez-Roige, Joel Gelernter, Arpana Agrawa. Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024-06-21. PMID:38906991. |
we explored the relationships between schizophrenia (scz; european ancestry n = 161,405; african ancestry n = 15,846), cannabis use disorder (canud; european ancestry n = 886,025; african ancestry n = 120,208), and ever-regular tobacco smoking (smk; european ancestry n = 805,431; african ancestry n = 24,278) using the largest available genome-wide studies of these phenotypes in individuals of african and european ancestries. |
2024-06-21 |
2024-06-24 |
Not clear |
| Mary F Brunette, Robert M Roth, Christi Trask, Jibran Y Khokhar, James C Ford, Soo Hwan Park, Sara M Hickey, Thomas Zeffiro, Haiyi Xi. Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder. Schizophrenia bulletin. 2024-06-20. PMID:38900958. |
randomized laboratory study of single-dose cannabis, dronabinol, and placebo in patients with schizophrenia and cannabis use disorder. |
2024-06-20 |
2024-06-23 |
Not clear |
| Mary F Brunette, Robert M Roth, Christi Trask, Jibran Y Khokhar, James C Ford, Soo Hwan Park, Sara M Hickey, Thomas Zeffiro, Haiyi Xi. Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder. Schizophrenia bulletin. 2024-06-20. PMID:38900958. |
up to 43% of people with schizophrenia have a lifetime cannabis use disorder (cud). |
2024-06-20 |
2024-06-23 |
Not clear |
| Meghan J Chenowet. Cracking the chicken and egg problem of schizophrenia and substance use: Genetic interplay between schizophrenia, cannabis use disorder, and tobacco smoking. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2024-06-11. PMID:38862577. |
cracking the chicken and egg problem of schizophrenia and substance use: genetic interplay between schizophrenia, cannabis use disorder, and tobacco smoking. |
2024-06-11 |
2024-06-14 |
chicken |
| Nikhil Nowbath, Nada Abdelatif, Gian Lipp. Comparing the medication costs of treating patients with schizophrenia who use cannabis with those who do not. The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa. vol 30. 2024-05-10. PMID:38726333. |
comparing the medication costs of treating patients with schizophrenia who use cannabis with those who do not. |
2024-05-10 |
2024-05-27 |
Not clear |
| Nikhil Nowbath, Nada Abdelatif, Gian Lipp. Comparing the medication costs of treating patients with schizophrenia who use cannabis with those who do not. The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa. vol 30. 2024-05-10. PMID:38726333. |
cannabis use is more prevalent among people with schizophrenia than in the general population. |
2024-05-10 |
2024-05-27 |
Not clear |
| Kennadi Johnson, Abby J Weldon, Melissa A Burmeiste. Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen. Frontiers in psychiatry. vol 15. 2024-05-08. PMID:38716117. |
differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen. |
2024-05-08 |
2024-05-27 |
Not clear |
| Kennadi Johnson, Abby J Weldon, Melissa A Burmeiste. Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen. Frontiers in psychiatry. vol 15. 2024-05-08. PMID:38716117. |
moreover, medication adherence is poor, and individuals with schizophrenia choose to self-medicate with illicit substances, including cannabis. |
2024-05-08 |
2024-05-27 |
Not clear |
| Kennadi Johnson, Abby J Weldon, Melissa A Burmeiste. Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen. Frontiers in psychiatry. vol 15. 2024-05-08. PMID:38716117. |
it is well-established that the delta-9-tetrahydrocannabinol (delta-9-thc) component of cannabis elicits psychotomimetic effects at high doses; worsens schizophrenia-related psychosis; commonly develops into cannabis use disorder in individuals with schizophrenia; and increases the risk of earlier-onset schizophrenia symptoms in those harboring genetic susceptibility. |
2024-05-08 |
2024-05-27 |
Not clear |
| Kennadi Johnson, Abby J Weldon, Melissa A Burmeiste. Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen. Frontiers in psychiatry. vol 15. 2024-05-08. PMID:38716117. |
however, individuals with schizophrenia commonly use cannabis and cannabis derivatives such as cannabidiol (cbd). |
2024-05-08 |
2024-05-27 |
Not clear |
| Aishwariya Brigit George, Abhishek Gupta, Raka Jain, Mamta Sood, Siddharth Sarka. Serum brain-derived neurotrophic factor level and its relation with cannabis use disorder and schizophrenia: A cross-sectional exploratory study in patients at a tertiary care hospital. Indian journal of pharmacology. vol 56. issue 2. 2024-04-30. PMID:38687312. |
serum brain-derived neurotrophic factor level and its relation with cannabis use disorder and schizophrenia: a cross-sectional exploratory study in patients at a tertiary care hospital. |
2024-04-30 |
2024-05-03 |
Not clear |
| Carsten Hjorthøj, Anne Stürup, Mette Karlsen, Helene Speyer, Merete Osler, Dost Ongur, Merete Nordentof. Use of antipsychotic medication, benzodiazepines, and psychiatric hospitalization in cannabis-related versus cannabis-unrelated schizophrenia - a nationwide, register-based cohort study. Psychological medicine. 2024-04-04. PMID:38571303. |
evidence suggests that cannabis may be a causal factor for development of schizophrenia. |
2024-04-04 |
2024-04-06 |
Not clear |
| Carsten Hjorthøj, Anne Stürup, Mette Karlsen, Helene Speyer, Merete Osler, Dost Ongur, Merete Nordentof. Use of antipsychotic medication, benzodiazepines, and psychiatric hospitalization in cannabis-related versus cannabis-unrelated schizophrenia - a nationwide, register-based cohort study. Psychological medicine. 2024-04-04. PMID:38571303. |
we aimed to investigate whether use of antipsychotic medication, benzodiazepines, and psychiatric service use differs among patients with schizophrenia depending on whether psychosis was precipitated by a diagnosis of cannabis use disorder (cud). |
2024-04-04 |
2024-04-06 |
Not clear |
| Natalia Mansur Haddad, Leonardo Peroni De Jesus, Mauricio Serpa, Martinus Van De Bilt, Leda Talib, Alana Costa, Wagner Gattaz, Alexandre Andrade Loc. Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication. European archives of psychiatry and clinical neuroscience. 2024-03-19. PMID:38502208. |
endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication. |
2024-03-19 |
2024-03-23 |
Not clear |